ATOS stock forecast
Our latest prediction for Atossa Therapeutics, Inc.'s stock price was made on the Nov. 15, 2017 when the stock price was at 4.08$.
In the short term (2weeks), ATOS's stock price should outperform the market by 3.25%. During that period the price should oscillate between -12.70% and +31.92%.
In the medium term (3months), ATOS's stock price should outperform the market by 0.14%. During that period the price should oscillate between -26.78% and +88.97%.Get email alerts
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.40$ per share.
The book value per share is 2.47$
Three months stock forecastNov. 15, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|